110 Additional Definitions. The definition of each of the following terms is set forth in the section of this Agreement indicated below: Defined Term Section AAA 13.3(a) AAA Rules 13.3(a) Agreement Preamble BLA 1.84 Cidara Preamble Cidara Indemnitee 12.1 Claim 12.1 Collaboration Agreement Recitals Development/Regulatory Milestone Event 6.2 Development/Regulatory Milestone Payment 6.2 Disclosing Party 9.1 Disputes 13.1 [***] 6.3 Effector Domain 1.5(a) EPO 1.53 [***] 6.2 Execution Date Preamble Existing Cidara Compound-Specific Patents 10.2(b) [***] 6.3 Indemnified Party 12.3 Indemnifying Party 12.3 Indirect Tax 7.4 Xxxxxxx Preamble Xxxxxxx Indemnitee 12.2 [***] 10.6(d) License 3.1 Linker 1.5(c) Losses 12.1 MAA 1.84 NDA 1.84 Outstanding Research Program Costs 2.2(d) Party/Parties Preamble [***] 6.2 PPACA 1.86(d) Pricing and Reimbursement Approvals 1.34 Protocol 13.3(d) PHSA 1.11 Receiving Party 9.1 Remainder 8.3 Representatives 9.1 Sales Milestone Event 6.3 Sales Milestone Payment 6.3 SEC 9.5(a) Senior Executive 13.2 Targeting Domain 1.5(b) Technology Transfer Schedule 4.1 Term 11.1 Upfront Payment 6.1 [***] 6.2 Withholding Tax Action 7.3
110 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[* * *]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Term Section “Acceleron Indemnitees” 11.7.1
110 Additional Definitions. Each of the following definitions is set forth in the Section of this Agreement indicated below: Definition Section Accounting Period 13.1 Acauired Party 21.2.4 Alliance Director 9.3 Bankruptcy Code 22 B-Cell Agreement Recitals Breachinq Party 21.2.1 CMO 10.2 Compulsory Share Percentage 12.10.4.3 Compulsory Sublicensee 1.25 Co-Promotion Agreement 11.2 Co-Promotion Option 11.2 Decision Period 16.9 Delayed Option 12.4.1 Disclosing Party 1.26 Eliqible Collaboration Product 4.1 Expert Committee 12.10.4.4 Exploit 3.2.1 First PoC 6.3.1 First TCL Opt Out 12.3.3.2 HPV 1.19 H-W Suit Notice 16.12 Indemnified Partv 18.3 Indemnifying Party 18.3 Initial Collaboration Product 6.2 Initial Termination Period 21.2.5 lnitiatinq Party 16.9 Joint Invention 1.56 JOT 9.6 JRDT 9.6 Licensed Antigen Product 1.63 Members 9.2.1 Non-Acauired Party 21.2.4 Non-Breaching Party 21.2.1 Other Collaboration Inventions 16.1 Patent Challenqe 17.12 Patent Term Extensions 16.14 Payment Currency 13.3 Peremptory Notice Period 21.2.1 Post-Option Product Specific Invention 16.1 Post-Option Roche Product Specific Invention 16.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Definition Section Post-Option SQZ Product Specific Invention 16.1 Pre-Option Product Specific Invention 16.1 Product Trademark 16.3 Publishing Notice 20.4 Publishing Party 20.4 Receiving Party 1.26 Reference Product Sponsor 16.13 Register 16.7 Relative Commercial Value 12.10.3 Roche Invention 1.56 Roche’s Matching Right 3.8 Roche Product Specific Patent Rights 16.5 Roche Product Trademarks 16.3 Roche Territory 1.104 Second TCL Opt Out 12.3.3.2 Sensitive Information 21.2.4 Settlement 16.9 SPCs 16.14 SQZ Invention 1.56 SQZ Platform Invention 16.1 SQZ Platform Patent Rights 16.4 SQZ Product Specific Patent Rights 16.4 SQZ Product Trademarks 16.3 SQZ Territory 1.104 SQZ Trademarks 16.3 Suit Notice 16.9 T-Cell Program Recitals Third Party Antigen 6.3.6 US Buy Out Option 12.12
110 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Term Section “Acceleron Indemnitees” 11.7.1
